Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Feb 18;75(6):620-628.
doi: 10.1016/j.jacc.2019.11.059.

Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies

Affiliations
Meta-Analysis

Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies

Janice M Bonsu et al. J Am Coll Cardiol. .

Abstract

Background: Cardiovascular disease (CVD) has become an increasingly common limitation to effective anticancer therapy. Yet, whether CVD events were consistently reported in pivotal trials supporting contemporary anticancer drugs is unknown.

Objectives: The authors sought to evaluate the incidence, consistency, and nature of CVD event reporting in cancer drug trials.

Methods: From the Drugs@FDA, clinicaltrials.gov, MEDLINE, and publicly available U.S. Food and Drug Administration (FDA) drug reviews, all reported CVD events across latter-phase (II and III) trials supporting FDA approval of anticancer drugs from 1998 to 2018 were evaluated. The primary outcome was the report of major adverse cardiovascular events (MACE), defined as incident myocardial infarction, stroke, heart failure, coronary revascularization, atrial fibrillation, or CVD death, irrespective of treatment arm. The secondary outcome was report of any CVD event. Pooled reported annualized incidence rates of MACE in those without baseline CVD were compared with reported large contemporary population rates using relative risks. Population risk differences for MACE were estimated. Differences in drug efficacy using pooled binary endpoint hazard ratios on the basis of the presence or absence of reported CVD were also assessed.

Results: Overall, there were 189 trials, evaluating 123 drugs, enrolling 97,365 participants (58.5 ± 5 years, 46.0% female, 72.5% on biologic, targeted, or immune-based therapies) with 148,138 person-years of follow-up. Over a median follow-up of 30 months, 1,148 incidents of MACE (375 heart failure, 253 myocardial infarction, 180 strokes, 65 atrial fibrillation, 29 revascularizations, and 246 CVD deaths; 792 in the intervention vs. 356 in the control arm; p < 0.01) were reported from the 62.4% of trials noting any CVD. The overall weighted-average incidence was 542 events per 100,000 person-years (716 per 100,000 in the intervention arm), compared with 1,408 among similar-aged non-cancer trial subjects (relative risk: 0.38; p < 0.01), translating into a risk difference of 866. There was no association between reporting CVD events and drug efficacy (hazard ratio: 0.68 vs. 0.67; p = 0.22).

Conclusions: Among pivotal clinical trials linked to contemporary FDA-approved cancer drugs, reported CVD event rates trail expected population rates.

Keywords: U.S. Food and Drug Administration; cancer clinical trials; cardio-oncology; cardiovascular disease; reporting of adverse events.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1. Reported Cardiovascular Events During Follow-Up
Events are stratified by cancer type (A), and therapeutic class (B), respectively. *The percentages reported reflect a denominator of the total number of trials within the subgroup considered. CVD = cardiovascular disease; GI = gastrointestinal; GU = genitourinary.
CENTRAL ILLUSTRATION
CENTRAL ILLUSTRATION. Cardiovascular Events in Pivotal Cancer Trials
(A) Proportional frequency of incident reported cardiovascular disease(CVD)events during cancer trial follow-up, compared with reported contemporary nontribal population estimates (–27) Plots stratified by CVD event types (hypertension not shown to due to high variation in rates based on drug type). (B) Reported versus observed cumulative CVD incidence rates, depicted in events per 100,000 person-years of available follow-up. Estimates reflect major adverse cardiovascular events from supporting anticancer trials compared with observed rates in a similar-aged contemporary population. *There were zero events reported for myocarditis

Comment in

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7–30. - PubMed
    1. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363: 711–23. - PMC - PubMed
    1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373:1627–39. - PMC - PubMed
    1. Schmid P, Adams S, Rugo HS, et al., IMpassion130 Trial Investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018;379:2108–21. - PubMed
    1. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364: 501–13. - PubMed

Publication types

MeSH terms

Substances